Cancer

MCL study

A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma

Trial overview

Disease

Mantle Cell Lymphoma

Topic

MCL study

Sponsor

Description

This is a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare LOXO-305 to other drugs that work in a similar way that have already been approved by the United States Food and Drug Administration (US FDA). Participation could last up to two years, and possibly longer, if the disease does not progress

Study details

For detailed information on this trial, please click here

Trial status

Actively recruiting

Location

Principle Investigator

Professor George Follows

MA, BM BCh (Oxon), PhD, FRCP, FRCPath

Consultant haematologist

Dr Jaimal Kothari

MA, BM BCh, MRCP, FRCPath

Haematologist

Oxford +1